Back to top
more

Spero Therapeutics (SPRO)

(Delayed Data from NSDQ)

$2.26 USD

2.26
2,221,224

+0.24 (11.88%)

Updated Jun 26, 2026 04:00 PM ET

After-Market: $2.24 -0.02 (-0.88%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.94%
2Buy18.19%
3Hold10.25%
4Sell5.78%
5Strong Sell3.18%
S&P50011.60%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (154 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

What's in Store for Edwards Lifesciences (EW) in Q3 Earnings?

by Zacks Equity Research

Outside the United States, Edwards Lifesciences (EW) TAVR sales growth will likely be driven by broad-based adoption of the SAPIEN platform.

Zacks Equity Research

Bio-Rad Laboratories (BIO) to Post Q3 Earnings: What Awaits?

by Zacks Equity Research

Bio-Rad (BIO) Life Science segment will likely have witnessed growth in Q3, driven by Droplet Digital PCR and qPCR products.

Zacks Equity Research

Insulet (PODD) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Insulet's (PODD) global new customer starts are expected to have been strong in the third quarter.

Zacks Equity Research

GE HealthCare (GEHC) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

GE HealthCare (GEHC) is expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.

Zacks Equity Research

Align Technology (ALGN) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Align Technology (ALGN) third-quarter 2023 results are likely to reflect strength in the Clear Aligner business.

Zacks Equity Research

Quest Diagnostics (DGX) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Quest Diagnostics (DGX) third-quarter 2023 results are likely to reflect continued strength in the base business.

Zacks Equity Research

All You Need to Know About Spero Therapeutics, Inc. (SPRO) Rating Upgrade to Buy

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Novartis (NVS) Announces Positive Long-Term Data on Leqvio

by Zacks Equity Research

Novartis (NVS) Leqvio shows consistent efficacy and safety beyond six years in patients with ASCVD.

Zacks Equity Research

Bristol Myers (BMY) Gets FDA Nod for Reblozyl Label Expansion

by Zacks Equity Research

Bristol Myers' (BMY) Reblozyl is now indicated in the United States as the first-line treatment of anemia in adults with lower-risk MDS who may require transfusions.